A carregar...
Synergistic MicroRNA Therapy in Liver Fibrotic Rat Using MRI‐Visible Nanocarrier Targeting Hepatic Stellate Cells
Liver fibrosis, as one of the leading causes of liver‐related morbidity and mortality, has no Food and Drug Administration (FDA)‐approved antifibrotic therapy yet. Although microRNA‐29b (miRNA‐29b) and microRNA‐122 (miRNA‐122) have great potential in treating liver fibrosis via regulating profibroti...
Na minha lista:
| Publicado no: | Adv Sci (Weinh) |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6402399/ https://ncbi.nlm.nih.gov/pubmed/30886803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/advs.201801809 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|